Global Bone Tumor Ablation Devices Market to Top $111 Million by 2027

The global bone tumor ablation devices market is expected to double over the next six years as clinicians increasingly turn to microwave energy to treat cancerous tumors, according to Coherent Market Insights.

Valued at $56.2 million in 2020, the market and is expected to swell 10.2 percent annually through 2027. Successful and multiple use of the microwave ablation technique for the treatment of various diseases is expected to increase sales of bone tumor ablation devices worldwide, thereby strengthening the position of the companies selling such products. For instance, doctors at National Taiwan University are successfully using microwave energy to minimally invasively treat tumors in the lung with higher local success rate of 84 percent compared to historical 67 percent to 78 percent reported, as of December 2019.
 
Major companies in the Europe region are involved in various growth strategies such collaboration, acquisition for research and development of new technology, in order to enhance their market presence. Medtronic plc acquired OsteoCool device technology from Baylis Medical in 2015.
 
Various key players in the market are entering the market through inorganic growth strategies such as mergers and acquisitions. August 2020, Olympus Corporation purchased Arc Medical Design Limited, a subsidiary of Norgine B.V. Under the agreement, Olympus acquired Arc Medical Design and obtained full rights of its medical products. Post-acquisition, Olympus Corporation is planning to design, manufacture, and distribute the products worldwide.
 
Furthermore, rising adoption of ablation devices by the surgeons for treatment in different therapeutic categories is expected to drive growth of the market in the Middle East. In 2019, IceCure Medical, an Israel-based company, received Israeli AMAR authorization (an Israeli Ministry of Health’s medical device regulation unit) to use its freezing technology in treatment of benign and malignant tumors of bones, liver, lymphatic tissue, lymph nodes, and endocrine glands.
 
The global bone tumor ablation devices market’s growth will be driven partly by the rising prevalence of bone cancer, or rare bone disorders worldwide. For instance, according to the National Organization for Rare Disorders, Ewing sarcoma affects males more often than females. It may affect individuals of any age, but most often occurs in individuals between 10 and 20 years of age. The annual incidence of Ewing sarcoma is 2.93 children per 1,000,000 in the United States. Around 200-250 children and adolescents in the United States are diagnosed with a tumor in the Ewing family of tumors, each year.
 
Key players in the North America bone tumor ablation devices market are focused on development of various bone tumor ablation devices, which is expected to drive growth of the market during the forecast period. In December 2015, DFINE Inc. announced the commercial launch of its Long SpineSTAR Ablation Instrument. Long SpineSTAR is the latest innovation by the Silicon Valley medical device manufacturer and is part of the company’s flagship STAR Tumor Ablation System.
 
Key players operating in the global bone tumor ablation devices market include Medtronic, Merit Medical Systems Inc., MedWaves Inc., AngioDynamics Inc., Olympus Corporation, Varian Medical Systems Inc., Mermaid Medical A/S, RF Medical Co. Ltd., and Misomix Inc.